The Effect of Cyanopyrrolidine Derivatives on the Activity of Prolyl Endopeptidase, Acute Exudative Inflammation and Visceral Pain in Mice

2020 ◽  
Vol 14 (2) ◽  
pp. 180-185
Author(s):  
E. A. Ivanova ◽  
N. N. Zolotov ◽  
V. F. Pozdnev ◽  
T. A. Voronina
2020 ◽  
Vol 66 (5) ◽  
pp. 423-426
Author(s):  
E.A. Ivanova ◽  
N.N. Zolotov ◽  
T.A. Voronina

A selective prolyl endopeptidase (PEP) inhibitor benzyloxycarbonyl-prolyl-prolinal (IC50 = 1,61±0,12 nmol/l) and a nonselective PEP inhibitor benzyloxycarbonyl-methionyl-cyanopyrrolidine (IC50 = 2,01±0,14 nmol/l) exhibit a comparable antiexudative effect at single doses of 2 mg/kg and 5 mg/kg (intraperitoneally) in outbred mice with peritonitis induced by 1% acetic acid. However, only benzyloxycarbonyl-methionyl-cyanopyrrolidine at a dose of 5 mg/kg reduces acetic acid induced pain in animals.


2010 ◽  
Vol 34 (8) ◽  
pp. S22-S22
Author(s):  
Rong Wei ◽  
Ying Gao ◽  
Xiaoxue Ding ◽  
Ziqi Yue ◽  
Sha Wu ◽  
...  

2001 ◽  
Vol 120 (5) ◽  
pp. A399-A399
Author(s):  
V LERAY ◽  
V SINNIGER ◽  
B ROCHE ◽  
M ODILECHRISTEN ◽  
S PHARMA ◽  
...  

2019 ◽  
Vol 3 (1) ◽  
Author(s):  
Eduardo E. Valdez-Morales ◽  
Tonatiuh Barrios-García ◽  
Alma Barajas-Espinosa ◽  
Raquel Guerrero Alba

2021 ◽  
Vol 4 (Supplement_1) ◽  
pp. 278-279
Author(s):  
M Defaye ◽  
N Abdullah ◽  
M Iftinca ◽  
C Altier

Abstract Background Long-lasting changes in neural pain circuits precipitate the transition from acute to chronic pain in patients living with inflammatory bowel diseases (IBDs). While significant improvement in IBD therapy has been made to reduce inflammation, a large subset of patients continues to suffer throughout quiescent phases of the disease, suggesting a high level of plasticity in nociceptive circuits during acute phases. The establishment of chronic visceral pain results from neuroplasticity in nociceptors first, then along the entire neural axis, wherein microglia, the resident immune cells of the central nervous system, are critically involved. Our lab has shown that spinal microglia were key in controlling chronic pain state in IBD. Using the Dextran Sodium Sulfate (DSS) model of colitis, we found that microglial G-CSF was able to sensitize colonic nociceptors that express the pain receptor TRPV1. While TRPV1+ nociceptors have been implicated in peripheral sensitization, their contribution to central sensitization via microglia remains unknown. Aims To investigate the role of TRPV1+ visceral afferents in microglial activation and chronic visceral pain. Methods We generated DREADD (Designer Receptors Exclusively Activated by Designer Drugs) mice in which TRPV1 sensory neurons can be inhibited (TRPV1-hM4Di) or activated (TRPV1-hM3Dq) in a time and tissue specific manner using the inert ligand Clozapine-N-Oxide (CNO). To test the inhibition of TRPV1 neurons in DSS-induced colitis, TRPV1-hM4Di mice were treated with DSS 2.5% or water for 7 days and received vehicle or CNO i.p. injection twice daily. To activate TRPV1 visceral afferents, TRPV1-hM3Dq mice received vehicle or CNO daily for 7 days, by oral gavage. After 7 days of treatment, visceral pain was evaluated by colorectal distension and spinal cords tissues were harvested to measure microglial activation. Results Our data validated the nociceptor specific expression and function of the DREADD in TRPV1-Cre mice. Inhibition of TRPV1 visceral afferents in DSS TRPV1-hM4Di mice was able to prevent the colitis-induced microglial activation and thus reduce visceral hypersensitivity. In contrast, activation of TRPV1 visceral afferents in TRPV1-hM3Dq mice was sufficient to drive microglial activation in the absence of colitis. Analysis of the proalgesic mediators derived from activated TRPV1-hM3Dq neurons identified ATP as a key factor of microglial activation. Conclusions Overall, these data provide novel insights into the mechanistic understanding of the gut/brain axis in chronic visceral pain and suggest a role of purinergic signaling that could be harnessed for testing effective therapeutic approaches to relieve pain in IBD patients. Funding Agencies CCCACHRI (Alberta Children’s Hospital Research Institute) and CSM (Cumming School of Medicine) postdoctoral fellowship


2021 ◽  
Vol 40 (2) ◽  
pp. 100811
Author(s):  
João Gonçalves ◽  
Carlos Rodrigues Almeida ◽  
Filipa Cunha ◽  
Maria Pinto

Sign in / Sign up

Export Citation Format

Share Document